The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial
A French randomized trial found that tailoring rituximab timing and dose to a patient's PLA2R antibody epitope-spreading profile nearly doubled 12-month remission rates compared with a standard protocol, without over-treating.
Study design
This randomized, prospective trial across 12 French hospitals enrolled 64 patients with PLA2R1-associated membranous nephropathy. The standard arm followed the GEMRITUX protocol (six months of symptomatic treatment, then low-dose rituximab if nephrotic syndrome persisted); the personalized arm gave immediate high-dose rituximab to patients showing epitope spreading and the standard protocol to non-spreaders.
Key findings
At 12 months, the personalized arm achieved clinical remission in 67% versus 35% in the standard arm (p=0.01), with better preservation of eGFR. Spontaneous remission rates and adverse event counts did not differ between arms, indicating the strategy did not simply over-treat patients.
Clinical implications
Epitope-spreading status can identify patients likely to fail standard low-dose rituximab, supporting earlier, more intensive B-cell depletion for immunologically severe disease while sparing lower-risk patients from unnecessary therapy.
Category
Research
Source
EClinicalMedicine
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.